Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.50 |
| ▸ | FABP7 | O15540 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29403341 | 0.84 | KMT2A (0.50) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL4214086 | 0.83 | KMT2A (0.52) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL9170700 | 0.82 | KMT2A (0.46) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL26931389 | 0.82 | KMT2A (0.46) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL120280 | 0.82 | FABP5 (0.50) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL5969982 | 0.81 | FABP5 (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL10037319 | 0.80 | KMT2A (0.51) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL30584150 | 0.80 | KMT2A (0.51) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL119279 | 0.79 | FABP5 (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL119531 | 0.79 | FABP5 (0.48) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9125880-B2 | Polymer conjugates of interferon-beta with enhanced biological potency | MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| EP-1667708-B9 | POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY | MOUNTAIN VIEW PHARMACEUTICALS (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-1667708-B1 | POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY | MOUNTAIN VIEW PHARMACEUTICALS (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20090105091-A1 | Modified Amino Acids | TECHNISCHE UNIVERSITAT WIEN (AT) | 2009-04-23 | — | — | US | disclosed |
| EP-1667708-A4 | POLYMER CONJUGATES OF INTERFERON- BETA WITH ENHANCED BIOLOGICAL POTENCY | MOUNTAIN VIEW PHARMACEUTICALS (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1989180-A1 | MODIFIED AMINO ACIDS | Technische Universität Wien (AT) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007095980-A1 | MODIFIED AMINO ACIDS | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2007-08-30 | — | — | WO | disclosed |
| EP-1826199-A1 | Modified amino acids | Technische Universität Wien (AT) | 2007-08-29 | — | — | EP | disclosed |
| EP-1667708-A2 | POLYMER CONJUGATES OF INTERFERON- BETA WITH ENHANCED BIOLOGICAL POTENCY | Mountain View Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2004060299-A2 | POLYMER CONJUGATES OF INTERFERON-BETA WITH ENHANCED BIOLOGICAL POTENCY | MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040126361-A1 | Diagnosis, therapy multiple sclerosis; anticancer agents; central nervous system disorders; autoimmune diseases | MOUNTAIN VIEW PHARMACEUTICALS, INC. | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105091-A1 | Modified Amino Acids | SLC1A2, NR1H4, OXGR1 | KMT2A 1541/4885FABP5 740/4885FABP7 575/4885 |
| US-20040126361-A1 | Diagnosis, therapy multiple sclerosis; anticancer agents; central nervous system disorders; autoimmune diseases | IFNAR1, IFNG, CD40 | KMT2A 3980/4885FABP5 1515/4885FABP7 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.